Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7865463 | 0.88 | KDM4C (0.37) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2525533 | 0.86 | PDE4B (0.41) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL7862734 | 0.85 | NPC1 (0.34) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL11993094 | 0.80 | KDM4E (0.32) | L3MBTL1 | |
| SCHEMBL7865626 | 0.79 | POLB (0.36) | — | |
| SCHEMBL2530598 | 0.78 | KDM4C (0.37) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL7862871 | 0.77 | LMNA (0.39) | KMT2AL3MBTL1 | |
| SCHEMBL11994821 | 0.76 | PDE4B (0.41) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL7865488 | 0.75 | ALDH1A1 (0.32) | L3MBTL1 | |
| SCHEMBL7865299 | 0.74 | PRKDC (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | KDM4C 4554/4885NPC1 1757/4885RAB9A 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.